The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.
Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;
Patients with unresectable recurrent or metastatic solid tumors;
There is at least one lesion could be measured;
An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
Patients with known active central nervous system (CNS) metastases;
Subjects who had other malignancy in five years before the first dose;
Patients with tumor-related pain that cannot be controlled as determined;
Patients with serious cardiovascular and cerebrovascular diseases;